Dipyridamole
- Generic Name
- Dipyridamole
- Brand Names
- Aggrenox, Persantine
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40N8O4
- CAS Number
- 58-32-2
- Unique Ingredient Identifier
- 64ALC7F90C
- Background
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
- Indication
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
- Associated Conditions
- Coronary Artery Disease (CAD), Postoperative Thromboembolism, Stroke, Thrombosis, Transient Ischemic Attack
- Associated Therapies
- Anti-platelet Therapy
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Northern Jiangsu People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04645550
- Locations
- 🇨🇳
Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China
Registry of IgA Nephropathy in Chinese Children
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 1200
- Registration Number
- NCT03015974
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Ariel University
- Target Recruit Count
- 40
- Registration Number
- NCT02782260
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 101
- Registration Number
- NCT02565693
- Locations
- 🇳🇱
Haaglanden MC, Den Haag, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
🇳🇱Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02273505
Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
- Conditions
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT02251184
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Yangzhou University
- Target Recruit Count
- 124
- Registration Number
- NCT02247414
- Locations
- 🇨🇳
Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Yangzhou University
- Target Recruit Count
- 60
- Registration Number
- NCT02238444
- Locations
- 🇨🇳
Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China
Dipyridamole for Immune Activation in HIV
- Conditions
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Sharon Riddler
- Target Recruit Count
- 40
- Registration Number
- NCT02121756
- Locations
- 🇺🇸
Pitt Treatment Evaluation Unit / University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Zalicus
- Target Recruit Count
- 294
- Registration Number
- NCT01369745
- Locations
- 🇺🇸
Zalicus Investigational Site, Toledo, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.